RecruitingPhase 2NCT06311227
Blood
Classic hairy cell leukemia
2
studies recruiting now
as of 7 Sept 2026
5
studies registered in total
as of 7 Sept 2026
1
countries with a recruiting site
as of 7 Sept 2026
11 May 2025
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 1 / Phase 2NCT06965114
Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia
Showing the 2 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
Search all Classic hairy cell leukemia studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Classic hairy cell leukemia study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Classic hairy cell leukemia
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the gene involved (BRAF).
Treatments being studied
4 approved treatments and 8 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Pentostatin (Nipent)Approved: Moxetumomab Pasudotox (Lumoxiti)Approved: Interferon Alfa-2b (Intron a)Approved: Cladribine (Cladribine)
Phase 2Vemurafenib (Zelboraf)
Phase 2Binimetinib (Mektovi)
Phase 2Encorafenib (Braftovi)
Phase 2Rituximab (Blitzima)
Phase 2Interferon Alfa-2a (Alpheon)
Phase 2Lmb-2
Phase 2Bl22
Phase 1Plixorafenib
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).